Recombinant adeno-associated viral vectors (rAAV) are used as gene therapy vectors to treat central nervous system (CNS) diseases. Despite their safety and broad tropism, important issues need to be corrected such as the limited payload capacity and the lack of small gene promoters providing long-term, pan-neuronal transgene expression in the CNS. Commonly used gene promoters are relatively large and can be repressed a few months after CNS transduction, risking the long-term performance of single-dose gene therapy applications. We used a whole-CNS screening approach based on systemic delivery of AAV-PHP.eB, iDisco+ tissue-clearing and light-sheet microscopy, to identify three small latency-associated promoters (LAP) from the herpesvirus pseudorabies virus (PRV). These promoters are LAP1 (404bp), LAP2 (498bp) and LAP1_2 (880bp). They drive chronic transcription of the virus encoded latency-associated transcript (LAT) during productive and latent phases of PRV infection. We observed stable, pan-neuronal transgene transcription and translation from AAV-LAP in the CNS for six months post AAV transduction. In several CNS areas, the number of cells expressing the transgene was higher for LAP2 than the large conventional EF1α promoter (1264bp). Our data suggests that the LAP are suitable candidates for viral vectorbased CNS gene therapies requiring chronic transgene expression after one-time viral-vector administration.
Introduction

Results
Small PRV LAP variants can drive transgene expression in neurons independently of herpesvirus infection.
The PRV LAP region includes at least two promoter regions defined here as LAP1 and LAP2 ( Figure 1A ). In the PRV genome, LAP1 and LAP2 are present in tandem as PRV LAP1_2.
These sequences alone or combined are capable of efficient expression of reporter transgenes in primary sympathetic neurons when used in AAV vectors without PRV infection ( Figure 1 C and 1D ). We analyzed the LAP nucleotide sequences to identify putative regulatory elements using Jasper 40, 41 , RSAT 42 and CTCFBSDB 2.0 43 software. We identified three cyclic AMP response element-binding protein (CREB) located upstream of the LAP1 TATA box and one upstream of LAP2 TATA box. Moreover, two CTCF motifs (CCCTCbinding factor) were detected upstream of LAP1 TATA box and one downstream of LAP2 TATA box. We identified downstream promoter elements (DPE) in LAP2, including CG boxes and four signal transducer and activator of transcription 1 (STAT1) sites. Additionally, there were lineage-determining TF 44 , such as SRY-Box 10 (SOX10) and oligodendrocyte transcription factor 2 (Olig2), upstream of the LAP1 TATA box and LAP2 TATA box, respectively ( Figure 1A ).
Four AAV recombinants were packaged into serotype PHP.eB capsids by standard methods.
We constructed three promoters: LAP1 (498 bp), LAP2 (404 bp) and LAP 1_2 (880 bp). We used the ubiquitous EF-1α promoter (1264 bp) as a positive control for transgene expression.
All four AAV recombinants expressed the fluorescent reporter mCherry ( Figure 1B) . To verify the in vitro performance of each promoter, we transduced rat primary superior cervical ganglia (SCG) neuronal cultures with 3 x 10 11 genomes of each AAV and quantified the relative mCherry fluorescence intensity (RFI) over a 90-day period. For neurons transduced with AAV-LAP1, mCherry expression increased abruptly at 11 days-post-infection (dpi) (6.42 4 RFI) but to a lower level when compared with AAV-LAP2, AAV-LAP1_2 and AAV-EF1α. AAV-LAP2 and AAV-EF1α expression increased ~125-fold more at 17 dpi (8.70 x 10 6 ; 8.01 x 10 6 RFI respectively) ( Figure 1C ). The highest level of expression by all four recombinants was at 28 dpi with LAP1 (2.9 x 10 5 RFI); LAP2 (1.36 x 10 7 RFI); LAP1_2 (4.36 x 10 6 RFI) and
EF1α (1.40 x 10 7 RFI) ( Figure 1C and 1D ). LAP2 and EF1α had the highest mCherry RFI (LAP2=EF1α>LAP1_2>LAP1). Between 38 dpi and 90 dpi, all four AAV recombinants showed a subtle but sustained RFI decrease ( Figure 1C ), most likely due to the senescence of primary SCG neurons after more than 100 days in culture. Importantly, all three AAV-LAP recombinants showed mCherry transcription in primary neurons for 90 days in the context of AAV transduction and in the absence of PRV infection.
Whole-CNS screening reveals pan-neuronal AAV-LAP transgene expression after six months.
We used AAV serotype PHP.eB for our promoter screening assay given the enhanced capacity to cross the BBB and transduce C57/BL6 mice CNS after systemic, intravascular delivery 7 . AAV-LAP1-mCherry, AAV-LAP2-mCherry, AAV-LAP1_2-mCherry and AAV-EF1α-mCherry were delivered by unilateral retro-orbital venous sinus injection of 4 × 10 11 viral genomes/mouse (vg/mouse). The brains and spinal cords were harvested 30 dpi and 190 dpi, as described in Figure 2A , to quantify mCherry transcription and translation. LAP-mCherry expression in the whole intact brain was determined after tissue was cleared and immunostained with iDISCO+ (immunolabeling-enabled three-dimensional imaging of solvent-cleared organs) by light-sheet microscopy and volumetric registration (Supplementary Movies S2, S3, S4, S5) 45, 46 . All four gene promoters showed stable mCherry expression at both 30 and 190 dpi. The density (number of mCherry positive cells per mm 3 of brain tissue) of LAP2 was higher than that of LAP1 and LAP1_2, and had no significant differences to EF1α (p < 0.05) in different areas of cortex: primary motor, secondary motor, primary somatosensory and supplemental somatosensory (Figures 2B -2E respectively); hippocampal formation ( Figure 2G ), pallidum ( Figure 2I ), hypothalamus ( Figure 2K ) and olfactory areas ( Figure 2P ). In cerebellum, LAP2 showed significatively higher mCherry density than LAP1, LAP1_2 and EF1α ( Figure 2O ). Furthermore, in striatum ( Figure 2H ); thalamus ( Figure 2J ); midbrain, motor and sensory areas ( Figure 2L and 2M), and hindbrain ( Figure 2N ), LAP2 and LAP1_2 showed significantly higher density than EF1α (p < 0.05).
Note that the LAP2 nucleotide sequence is 68% shorter than that of EF1α yet outperforms EF1α density in several brain areas. To further validate LAP transgene expression in the CNS, we assessed mCherry protein expression by immunohistochemistry (IHC) in brain sagittal sections at 30 and 190 dpi ( Figure 3A Figure 3H1 -3H4) at 30 dpi. Importantly, mCherry expression was stable for all three LAP variants at 190 dpi and similar to that of the large promoter EF1α ( Figure 3E5 -3E8, 3F5 -3F8, 3G5 -3G8 and 3H5 -3H8). Next, we quantified mCherry expression at 30 and 190 dpi. The mCherry RFI was similar for all AAV promoters with no significant differences (p < 0.05) ( Figure 3I1 -3I4). We subsequently quantified the number of mCherry positive cells per pixels 2 190 dpi. In cortex, the number of LAP2-mCherry expressing cells was higher than those observed for LAP1-mCherry and LAP1_2-mCherry [LAP2: 297 ± 19.82 vs. LAP1: 149 ± 5.61 vs LAP1_2: 168 ± 9.22 (n = 6, p <0.001) ( Figure   3J1 ). In dentate gyrus, striatum and cerebellum the number of mCherry positive cells was similar for all LAP variants and EF1α ( Figure 3J2 -3J4 ). We conclude that all AAV-LAP variants promote mCherry expression in the brain, further demonstrating that a single administration of AAV-LAP recombinants is sufficient to drive long term, pan-neuronal transgene expression in the mouse CNS.
The small LAP2 promoter variant drives strong and stable pan-neuronal transgene transcription and translation after systemic AAV administration.
We compared the efficacy of mCherry expression under the control of different PRV LAP Table 1 ). Although AAV-LAP1 and AAV-LAP1_2 mCherry RFI levels were stable and not significantly different at 30 and 190 days in cortex, dentate gyrus, striatum and cerebellum ( Figure 4E1 -4E4, Table 1 ), both promoters showed significantly less transgene expression (RFI) compared to LAP2 and EF1α.
Since mRNA half-life is typically shorter than that of the translated protein 47 , we measured mCherry transcripts in AAV-LAP2 and AAV-EF1α transduced brains 190 dpi with a mCherryspecific riboprobe. Fluorescent in situ hybridization (FISH) showed abundant AAV-LAP2 mCherry RNA in cortex, dentate gyrus, striatum, cerebellum and olfactory bulb ( Figure 5 ), further confirming that PRV LAP2 can drive chronic and robust transgene transcription in the CNS.
AAV-LAP transgene expression in the brain is predominant in neurons but not in glial cells
The tropism and specificity of AAV transduction and subsequent transgene expression depends on the AAV serotype 4, 6 and the gene promoter 8, 48, 49 . To characterize which celltypes showed AAV-LAP-mCherry expression after systemic AAV-PHP.eB delivery, we performed co-immunostaining of mCherry protein with markers for neurons (NeuN), oligodencrocytes (Olig2), microglia (Iba1) and astrocytes (S100) in cortex and dentate gyrus.
Co-staining with NeuN and mCherry revealed that over 88% of the neurons imaged expressed mCherry driven by the different AAV-LAP variants in both cortex and dentate gyrus ( Figure 6A1 -6B4, 6E). Conversely, less than 4% of mCherry-positive oligodendrocytes were detected for all LAP variants ( Figure 6C1 -6D4, 6F). Moreover, we observed no co-labelling of mCherry with microglia (Iba1) and astrocyte (S100) markers for any of the AAV-LAP recombinants ( Figure S1 ). Overall, these results demonstrate that in the context of systemic brain transduction with AAV-PHP.eB, LAP-mCherry expression is abundant in neurons but not in glial cells.
AAV-LAP constructs exhibit broad, stable and long-term transgene expression throughout the spinal cord
In addition to the brain, we evaluated AAV-LAP performance in spinal cord, where the serotype PHP.eB has shown widespread transduction of gray matter 7, 8 . We observed abundant native mCherry expression in both dorsal and ventral horns of the spinal cord at cervical, thoracic and lumbar levels 190 dpi ( Figure 7A -7D). Native mCherry RFI was similar for all promoters with no statistically significant differences (p < 0.05) ( Figure 7E ). However, the LAP2 and LAP1_2 recombinants showed the highest density of mCherry-positive cells per pixels 2 , followed by EF1α and LAP1 respectively; LAP2=LAP1_2>EF1α>LAP1 ( Figure   7F ). Therefore, all three PRV LAP variants effectively mediate pan-neuronal, long-term transgene expression in the spinal cord.
Discussion
Gene therapy has been used to restore gene function in specific target cells in neurological disorders 50 . Gene transfer by systemic vector delivery via peripheral vascular transduction can be difficult for efficient expression in a neuron-specific or pan-neuronal fashion in the CNS 51 . Recombinant AAV vectors are among the most efficient vehicles to achieve gene expression in the CNS 2, 52 . Moreover, engineered AAV capsids have shown improved CNS transduction and enhanced capacity to cross the BBB with higher efficiency than naturallyoccurring serotypes 6, 7, 53, 54 . Despite these advances, AAV gene therapy is hindered by the small payload size limit of 4.9 Kb for the AAV capsid 55 . For example, CNS therapies for Pompe disease 56 and Parkinson's disease 57 are based on delivery of relatively large genes such as GAA (2.9 Kb) and GDNF (2.5 Kb). For these and other similar cases, the use of small, non-repressible promoters are ideal replacements for larger promoters or even smaller CMV and hSyn promoters shown to be quickly repressed after delivery 14, 15 .
We identified three small pan-neuronal promoters isolated from the genome of the alphaherpesvirus PRV, showing efficient and long-term transgene expression in the mouse CNS after systemic AAV PHP.eB delivery. Our results demonstrate that these small PRV LAP variants can drive long-term expression of a reporter transgene (> 6 months) in brain and spinal cord. PRV LAP uniformly transduced neurons in the cortex, striatum, dentate gyrus and cerebellum. The distribution of mCherry-positive cells was not significantly different between LAP variants in the dentate gyrus, striatum and cerebellum. However, LAP2 transgene expression was significantly higher in cortex compared to LAP1 and LAP1_2. Our whole-brain screening assay demonstrated that the LAP2 variant of only 402 bp can drive stronger mCherry expression than the larger LAP1 and LAP1_2 sequences. Moreover, we detected abundant mCherry mRNA transcribed from LAP2 in every screened brain region at 190 dpi. These results demonstrate both efficient transcription and translation driven from the small PRV LAP2 in CNS after systemic AAV-LAP2 delivery in the absence of PRV infection.
Although the LAP1-mCherry cell density was significatively lower than that for LAP2, mCherry expression remained stable and long-lasting. Therefore, LAP1 might be useful in cases where low amounts of the therapeutic protein are needed (e.g. enzyme deficiencies) or for crosscorrection to non-transduced cells. For example, for lysosomal enzyme deficiency 19 and mucopolysaccharidosis VII diseases 58 , where the enzyme restored by AAV therapy can be secreted from the transduced cell and improve neighboring diseased cells.
AAV tropism is determined primarily by interactions between the capsid and specific receptors in susceptible and permissive cells 4, 6 . Different AAV serotypes have different tissue tropism.
However, the promoter sequence and other sequences included in the vector such as the inverted terminal repeat sequence (ITR), can have a substantial impact on tropism 59 . In addition, the promoter region transcribing the transgene is critically important to optimize the AAV vector's performance. Efficient transgene expression either in a broad or cell-type specific fashion, requires binding and action of cell-derived TF to the promoter region 8, 60 .
Changes in the neuronal environment such as aging or differentiation, also can alter the recruitment of cell-specific regulatory proteins and therefore gene expression in the CNS 61 .
Our analysis of the PRV LAP sequence identified DPE in LAP2, which could control transgene expression onset, duration and cell-type specificity. Additionally, we identified four STAT1 motifs, that in HSV-1 LAP seem to regulate viral reactivation from latency 62 . Strikingly, we identified one of these STAT1 motifs in PRV LAP2 co-localizing with the TATA box and an Olig2 motif, a known multifaceted TF promoting neuronal and oligodendrocyte fates 63 . The proximity effects associated with these motifs and the transcriptional start site could explain the different levels of CNS transgene expression between LAP2, LAP1 and LAP1_2.
However, further investigation of these regulatory elements is required to understand the finetuning control of PRV LAP2 activity. Additionally, we found one CTCF motif downstream of the LAP2 TATA box, which could have a role in the resistance to epigenetic silencing during latency, as shown for HSV-1 64, 65 . Indeed, Zimmerman and colleagues found that insertion of a CTCF motif downstream of the EF1α promoter increased transgene expression significantly compared to native EF1α and CMV promoters 66 . Interestingly, the insertion of a secondary CTCF motif downstream of the CMV TATA box, had no effect on luciferase reporter expression, presumably due to the redundant presence of a native CTCF motif 66 . Accordingly, gene expression is susceptible to changes depending of the genetic context and sequencespecific DNA binding proteins. The recruitment of specific TF from different host cells can modulate transgene transcription by the same mechanisms regulating resistance to inactivation during latency. Insulator elements like the CTCF-binding factor are independently regulated 67 and can protect promoter regions from repression by heterochromatin, maintaining long-lasting transcription 64 .
Histological assessment of cell-specific transduction by colocalization of LAP-mCherry, glial and neuronal markers, revealed that LAP variants express more efficiently in neurons than glia, in cortex and dentate gyrus. LAP-mCherry positive cells colocalized predominantly with neuron-specific markers, and to a lesser extent with oligodendrocytes but not microglia or astrocytes. Based on these findings, we conclude that PRV LAP sequences have a panneuronal promoter profile in the CNS after PHP.eB systemic delivery. This activity has also been found for the HSV LAP due to the presence of a CRE motif upstream of the TATA box [68] [69] [70] . Transgenic mouse lines containing PRV LAP1 and LAP2 demonstrated that LAP are neuron-specific promoters in the absence of other viral proteins and that neuronal TF are sufficient to activate LAP in vivo 39 . Importantly, AAV-PHP.eB transduces neurons predominantly 7 , and the combination of this capsid variant with PRV LAP sequences exhibits a strong, long-lasting, pan-neuronal expression profile in the CNS. Future research should asses the transgene expression profile of PRV LAP and different AAV serotypes in tissue/organs other than the CNS and in animal models other than rodents. We predict that PRV LAP can be used not only in the context of recombinant viral vectors (AAV, adenovirus, lentivirus, herpesvirus), but also with non-viral gene delivery platforms. The natural host of PRV is the adult swine, but the virus has an extremely broad tropism and can infect some birds, fish and many types of mammals including some primates 71 . Moreover, human cells in culture are susceptible to PRV infection and there have been some reports of zoonotic infections 72 . Therefore, the PRV LAP sequence could be naturally optimized for gene therapyapplications requiring efficient and long-term transgene expression in several different mammals including humans.
In summary, we have demonstrated that PRV LAP promoter activity is independent of PRV infection and found that small AAV-PHP.eB-LAP variants express transgenes in a stable and pan-neuronal fashion in brain and spinal cord (CNS). Long-term transgene transcription and translation is paramount for effective and long-lasting single-dose gene therapy applications.
Thus, PRV LAPs may be useful for the treatment of genetic CNS diseases after one-time viral-vector administration. 3, 5, 7, 9, 11, 14, 17, 21, 24, 28, 31, 34, 38, 41, 45, 49, 52, 59, 67, 73, 82 , and 90 days post infection (dpi) with 3 x 10 11 vg. Data are represented as mean ± SEM; n = 3 SCG culture dishes per group. (D) AAV-driven mCherry expression in SCG neurons is shown at 28 dpi with LAP1-mCherry, LAP2-mCherry, LAP1_2-mCherry and EF1α-mCherry. Scale bar = 500 µm. nucleus; Cb, cerebellum; Thal, thalamus; Pn, pons; Hypo, hypothalamus; Str, striatum; OB, olfactory bulb. Scale bar = 1mm. Representative confocal images show anti-mCherry signal (green) for AAV-LAP1 (E1, E5) in cortex, (F1, F5) dentate gyrus, (G1, G5) striatum and (H1, H5) cerebellum at 30 and 190 dpi, respectively. AAV-LAP2 (E2, E6) in cortex, (F2, F6) in the dentate gyrus, (G2, G6) in the striatum and (H2, H6) in cerebellum at 30 and 190 dpi, respectively. AAV-LAP1_2 (E3, E7) in cortex, (F3, F7) in the dentate gyrus, (G3, G7) in the striatum and (H3, H7) in cerebellum at 30 and 190 dpi, respectively. AAV-EF1α (E4, E8) in cortex, (F4, F8) in the dentate gyrus, (G4, G8) in the striatum and (H4, H8) in cerebellum at 30 and 190 dpi, respectively. All images are stack confocal sections. Scale bar = 100 µm. Quantification of the indirect fluorescence intensity of anti-mCherry signal driven by AAV-LAP variants and AAV-EF1α at 30 and 190 dpi is shown in (I1) cortex, (I2) dentate gyrus, (I3) striatum, (I4) cerebellum. Quantification of the number of cells expressing mCherry signal per pixels 2 by IHC at 190 dpi is shown in (J1) cortex, (J2) dentate gyrus, (J3) striatum and (J4) cerebellum. Data are represented as mean ± SEM; n = 2 (six tissue sections were analyzed for each animal). For A, data was normalized to a vehicle-injected control animal. Significance was determined with Student's t-test (if only two groups were compared) or analysis of variance one-way (ANOVA) followed by Bonferroni post hoc test (if more than two groups were compared). A p value < 0.05 was considered to be statically significant (*p < 0.033; **p < 0.002; ***p < 0.001).
Figure 4. LAP2 drives stable and long-term transgene expression in the brain.
Representative confocal images show native mCherry fluorescence (red) for AAV-LAP1 (A1, A5) in cortex, (B1, B5) dentate gyrus, (C1, C5) striatum and (D1, D5) cerebellum at 30 and 190 dpi, respectively. AAV-LAP2 (A2, A6) in cortex, (B2, B6) in the dentate gyrus, (C2, C6) in the striatum and (D2, D6) in cerebellum at 30 and 190 dpi, respectively. AAV-LAP1_2 (A3, A7) in cortex, (B3, B7) in the dentate gyrus, (C3, C7) in the striatum and (D3, D7) in cerebellum at 30 and 190 dpi, respectively. AAV-EF1α (A4, A8) in cortex, (B4, B8) in the dentate gyrus, (C4, C8) in the striatum and (D4, D8) in cerebellum at 30 and 190 dpi, respectively. All images are stack confocal sections. Scale bar = 100 µm. Quantification of the direct fluorescence intensity (RFI) of native mCherry signal driven by AAV-LAP variants and AAV-EF1α at 30 and 190 dpi is shown in (E1) cortex, (E2) dentate gyrus, (E3) striatum, (E4) cerebellum. Data are represented as mean ± SEM; n = 2 (six tissue sections were analyzed for each animal) and was normalized to a vehicle-injected control animal. Significance was determined with Student's t-test (if only two groups were compared) or analysis of variance one-way (ANOVA) followed by Bonferroni post hoc test (if more than two groups were compared). A p value < 0.05 was considered to be statically significant (*p < 0.033; **p < 0.002; ***p < 0.001). 
Materials and Methods
Construction of PRV LAP promoters
The 
Construction of AAV Vectors
All expression cassettes were packaged into AAV-PhP.eB capsids (gift from Daniela Gradinaru, Addgene plasmid # 103005) at the Princeton Neuroscience Institute Viral Core Facility and purified by iodixanol step gradient and column ultrafiltration as previously described 7, 73 . Capsid-protected viral genomes were measured by TaqMan qPCR and reported as genome copies per milliliter (GC/ml).
Animals
Animal studies were performed following guidelines and protocols approved by the (Scottsdale, PA). Adult (4 to 6-week-old) wild type C57BL/6J male mice were obtained from Jackson Laboratory (The Jackson Laboratory, Bar Harbor, ME). Mice had at least 48 hr of acclimation to the holding facility in the Princeton Neuroscience Institute vivarium before experimental procedures were performed.
Primary superior cervical ganglia cell culture SCG neurons from rat embryos (E17) were cultured in trichambers as previously described 74 .
Briefly, SCG were dissociated with trypsin (2.5 mg/ml, Sigma-Aldrich, The Woodlands, TX) and plated on poly-O-Ornithine and laminin-coated dishes with media containing neurobasal media supplemented with 2% B-27, 100 ng/ml nerve growth factor (NGF), and 1% penicillinstreptomycin-glutamine (Thermo Fisher Scientific, Rockford, IL). Approximately two-thirds of a single ganglia were placed for S (soma) compartment of the trichamber. Three days post seeding, culture medium was treated with 0.1 mM cytosine-D-arabinofuranoside, Ara C (Sigma-Aldrich, The Woodlands, TX) for at least 2 days to eliminate dividing, nonneuronal cells. Culture media was replaced every 5 days, and neurons were incubated at 37 °C with 5% CO2.
Retro-orbital sinus injection
Intravenous administration of AAV vectors was performed in mice by unilateral injection into the retro-orbital venous sinus 75 . Animals were anesthetized using ketamine (80 mg/kg)/xylazine (10 mg/kg) cocktail prior to the procedure. Once unresponsive, animals were placed in lateral recumbence for injection into the medial canthus. Injection volume was 100 µl containing a total of 4 x 10 11 viral genomes administered with a 29G1/2 insulin syringe.
Animals were placed on regulated heating pads and monitored until ambulant.
Tissue processing and histological procedures
Mice were anesthetized with an overdose of ketamine (400 mg/kg)/xylazine ( and stored in the dark at RT until imaged.
Light-sheet microscopy and analysis of cleared tissue
After immunolabeling and clearing, brain volumes were acquired using a light-sheet Ultramicroscope II (LaVision Biotec, Bielefeld, Germany). Brain halves were glued in the horizontal orientation on a custom-designed 3D-printed holder 45, 46 and submerged in DBE. were sigmoidally blended at the midline. Autofluorescent volumes were registered to the volumetric Allen brain atlas (2015) using affine and b-spline transformations, as described by
Brains
Renier and colleagues 45, 46 . To account for movement during acquisition and different imaging parameters between channels, cell signal volumes were registered to autofluorescent volumes with an affine transform. Brain volumes were analyzed with our modified ClearMap software: "ClearMap_cluster" (github.com/PrincetonUniversity/clearmap_cluster), compatible with high performance computing clusters. Between five and ten 500 um volumes per brain region were analyzed for each animal to obtain the average local density measurements. For all analyzed samples, detected objects on brain edges and ventricles were eroded by 75 μm from the edge of the structure to minimize false positives.
RNAscope in situ hybridization
Brain cryosections were mounted on superfrost plus adhesion slides (Thermo Fisher, Waltham, MA) and stored at -80 °C. RNA staining was performed using the RNAscope multiplex fluorescent reagent kit (Advanced Cell Diagnostics (ACD), Newark, CA) following the manufacturer's protocol. The mCherry probe ACD# 431201-C2 was used. Slices were pretreated with protease IV for 30 min at 40 °C, followed by probe incubation for 2 h at 40 °C.
Then, different amplifier solutions were performed for 30, 30 and 15 min at 40 °C. Signal was detected with TSA plus fluorescein system (Perkin Elmer, Waltham, MA). Incubation steps were done in the ACD HybEZ hybridization system. Slides were counterstained with DAPI for 30 s at RT. Finally, slides were mounted with VECTASHIELD Vibrance antifade mounting medium (Vector Laboratories, Burlingame, CA).
Statistics
Statistical data analysis was performed using GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA). Two-tailed Student's test was used to compare between two groups, and non-parametric one-way ANOVA test followed by a Bonferroni multiple comparison post-test to compare among multiple groups. A p value < 0.05 was considered to be statically significant. Data are represented as the mean with SEM.
Supplemental data
Supplementary Figure S1 and movie S2, S3, S4, S5 are available online. Figure S1 . AAV-LAP transgene expression is not detected in microglia and astrocytes.
Supplemental Figures
(A, B) Representative confocal images of AAV-mediated mCherry expression (red) in microglia (green label for the glial marker Iba1); (C, D) astrocytes (green label for the astrocyte marker S100), in both cortex and dentate gyrus at 30 dpi. Absence of co-labelling of mCherry and astrocytes or microglia is indicated with stars (*). Cells were counterstained with DAPI (blue). (A1, C1) AAV-LAP1 in cortex, (B1, D1) AAV-LAP1 in dentate gyrus; (A2, C2) AAV-LAP2 in cortex, (B2, D2) AAV-LAP2 in dentate gyrus; (A3, C3) AAV-LAP1_2 in cortex, (B3, D3) AAV-LAP1_2 in dentate gyrus and (A4, C4) AAV-EF1α in cortex, (B4, D4) AAV-EF1α in dentate gyrus. Images are stack confocal sections. Scale bar = 100 µm. 
